Epigenetic inhibitors that target to chromatin modifying enzymes such as HATs, HDACs,HMTs, HDMTs and DNMTs are novel candidate in drug discovery for cancer treatment. TACGen offers epigentic inhibitor discovery service at three lever, including whole genome mapping, specific gene locus validation and general high throughput epigenetic inhibitor screening in vitro and in vivo.
